GHP Q3 2018

GHP / Q3 2018 5 NEWS , Increasing demand for personalised treatments, an ageing pop- ulation, the rise of new manufacturing technologies and ‘digital’ medicines (drugs with an ingestible sensor embedded in them), are some of the primary growth opportunities for UK pharmaceu- ticals companies according to a new report from Santander and manufacturing organisation EEF1. The five key areas for growth are: 1. Pe r s o n a l - ised medicine The rise of “personalised” or “precision” medicine is rev- olutionising the way doctors and pharmaceutical com- panies approach disease. Using genetic sequencing, medical professionals are now able to separate people with similar symptoms into far narrower groups and target medicines accordingly. 2. Technology The possibilities of using technology in pharmaceuti- cal manufacturing are almost endless, with the potential to improve efficiency and reduce costs continuing to evolve. One of the most strik- ing recent developments, however, is the emergence of digital medicine. Digital medicine, or digital pills, are drugs with an ingestible sen- sor embedded in them that records when the medication was taken. 3. Accelerated Access Path- way The high costs of developing a drug and getting it to mar- ket are prohibitive factors for many manufacturers. The UK Government has recog- nised this and in 2016 com- missioned the Accelerated Access Review, which had the ultimate aim of getting the best technologies – be it drugs, devices or diagnostics to patients more quickly and cheaply. 4. Ageing population Populations across the indus- trial world are living longer. According to projections from the ONS, by 2046 a quarter of the UK population will be aged 65 or over, compared to just 18% in 2016 and 14% in 1976, meaning the need for new and innovative health- Covers ApoGraft’s uses, methods and devices in stem cell selection for con- ditions including GvHD. In addition, it is expect- ed to give company protection against devices that make use of apoptosis for cell selection. Cellect Biotechnology Ltd. (Nas- daq: APOP), a developer of a novel stem cell production tech- nology, announced today the Eu- ropean Patent Office has granted the company a patent for its plat- form ApoGraft™ technology and ApoTainer™ device titled, “Devic- es and Methods for Selecting Ap- optosis-Signaling Resistant Cells, and Uses Thereof”. The patent addresses Cellect’s devices and methods for specifi- cally selecting desired stem cells from a heterogeneous cell popu- lation for use in a range of medi- cal indications. Through negative selection, Cellect’s technology identifies mature cells that can be harmful to the recipient and selectively eliminates those cells through apoptosis (cell death). Cellect’s patented technology is designed to produce safe and am- Cellect Granted Key European Patent for Its StemCell Selection Technology ple quantities of stem cells ready for dosing in patients in a wide range of disease states from on- cology to auto-immune diseases. The latest patent granted to the Company, covers claims includ- ing Cellect’s method for prevent- ing graft vs. host disease (GvHD) while retaining potent anti-cancer graft vs. tumor (GvT) activity us- ing the ApoTainer™ device. “This patent in Europe further expands our robust intellectual property estate which includes seven families of global patent applications with several issued in the U.S. and Eu. for the con- cept of using apoptosis for stem cell selection, methods of use, and composition of matter for the ApoTainer™. We expect to have protection against other devices looking to use apoptosis-inducing ligands, as indicated in the pat- ent, for the process of cell selec- tion,” stated Cellect CEO Dr. Shai Yarkoni. “We believe the value of this patent is underscored by the favourable initial results reported in our open label Phase I/II trial in GvHD which is actively recruiting and treating patients.” care products will be greater than ever before. 5. Demand from emerging markets Emerging markets (including China, Brazil and India) rep- resent an exceptional oppor- tunity for the pharmaceutical industry. According to BMI Research, pharmaceutical revenues from emerging markets could reach $490 billion by 2025, up 227% from the level in 2010. Paul Brooks, UK Head of Man- ufacturing at Santander Corpo- rate & Commercial said: “The sector has a number of opportuni- ties for growth both at home and abroad. As we live longer as a society, so the healthcare sector will need more innovative solu- tions to keep us healthier. We will see the rise of a truly personalised approach to medicine and the UK is well placed to take advantage of this, particularly in emerging markets such as China, Brazil and India, as their economies contin- ue to grow. Santander can help British companies make the nec- essary connections in those over- seas market and showcase their expertise and innovation through our sector and country specialists as well as with our trade missions and global networks.” Martyn Jenkins, Economist at EEF said: “The UK pharma- ceuticals sector has taken off in recent times, contributing signifi- cantly not just to the UK economy but to the health of populations both here and abroad. “Looking ahead the sector must grasp the opportunities on offer from the developments in technol- ogy and medicine to help combat the challenges of an ageing pop- ulation, while policy makers must continue to support this vital sec- tor by ensuring the UK business environment is cost competitive, trade links are retained and the longstanding productivity issue is addressed.”